Related Experiment Video
Updated: Jul 20, 2026

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination
Published on: September 25, 2014
Penicillin resistance and serotyping of Streptococcus pneumoniae in Latin America
Paulo Camargos1, Gilberto Bueno Fischer, Helena Mocelin
1Department of Paediatrics, Medical School, Federal University of Minas Geraias, Avenida Alfredo Balena, 190/Room 4061, 30130-100 Belo Horizonte, and Respiratory Department, Hospital da Criança Santo Antonio, Porto Alegre, Brazil. pcamargs@medicina.ufmg.br
Insights
Streptococcus pneumoniae causes severe pneumonia in young children. A study found prevalent serotypes and penicillin resistance in Latin America, with limited vaccine representation.
Area of Science:
- Pediatric infectious diseases
- Bacteriology
- Vaccinology
Background:
- Streptococcus pneumoniae is a leading cause of bacterial pneumonia in children under five, particularly in developing nations.
- High mortality rates associated with Strep. pneumoniae pneumonia necessitate effective prevention and treatment strategies.
Purpose of the Study:
- To identify prevalent Streptococcus pneumoniae serotypes in Latin America.
- To assess the representativity of these serotypes in current conjugated vaccines.
- To determine the level of penicillin resistance in isolated strains.
Main Methods:
- The Regional System for Vaccines Group (SIREVA) of the pan-American Health Organisation (PAHO) conducted a study across six Latin American countries.
- Serotyping of Streptococcus pneumoniae isolates was performed.
- Penicillin resistance levels were determined for the identified serotypes.
Main Results:
- Several serotypes, including 14, 5, 1, 6A/B, 23F, 7F, 9V, 19F, 18C, 19A, and 9N, were found to be prevalent in the region.
- Penicillin resistance varied significantly, from 2% in Brazil to 21.1% in Mexico.
- Only 58% of the isolated serotypes were covered by the seven-valent conjugated vaccine.
Conclusions:
- Continued surveillance of Streptococcus pneumoniae serotypes and antibiotic resistance is crucial for Latin America.
- The current seven-valent vaccine does not fully cover the prevalent serotypes in the region.
- Ongoing monitoring is essential to guide the selection of appropriate conjugated vaccine formulations for optimal public health impact.
Abstract:
Streptococcus pneumoniae (Strep. pneumoniae) is the main cause of bacterial pneumonia in children less than 5 years of age, with high mortality rates in developing countries. In 1993, the Regional System for Vaccines Group (SIREVA) of the pan-American Health Organisation (PAHO) began a study involving six Latin American countries to identify serotypes and their representativity in the new conjugated vaccines, and to determine the degree of resistance to penicillin. Serotypes 14 (highest resistance level), 5, 1, 6A/B, 23F, 7F, 9V, 19F, 18C, 19A, 9N, were prevalent in the region, with some differences among countries. Although resistance to penicillin ranged from 2% (Brazil) to 21.1% (Mexico), studies have shown that pneumonia caused by Strep. pneumoniae with diminished sensitivity to penillin can be treated with this antibiotic. Only 58% of the serotypes isolated in the region studied were represented in the seven-valent vaccine. Continual surveillance is essential to determine which formulation of conjugated vaccine will be suitable for use in Latin America.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Atypical Pneumonia
Development of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis
Production of Antibiotics

